Literature DB >> 16630077

Vascular endothelial growth factor gene polymorphisms increase the risk to develop psoriasis.

S Barile1, E Medda, L Nisticò, V Bordignon, P Cordiali-Fei, M Carducci, A Rainaldi, R Marinelli, C Bonifati.   

Abstract

We investigated the relationship between eight polymorphisms in the gene encoding for vascular endothelial growth factor (VEGF) (-1540C > A, -1512Ins18, -1451C > T, -460T > C, -160C > T, -152G > A, -116G > A and +405G > C) and plaque-type psoriasis stratified for age at onset, gender and family history of dermatosis. For this purpose, 117 patients with chronic plaque-type psoriasis and 215 healthy subjects were enrolled. We found that being homozygous -1540AA, -1512InsIns, -1451TT, -460CC and -152AA conferred a significant risk in developing psoriasis compared with heterozygous (-1540CA, -1512 + Ins, -1451CT, -460CT and -152AG) and homozygous genotypes (-1540CC, -1512 + +-1451CC, -460TT and -152GG) grouped together [odds ratio (ORs) = 1.73, 1.73, 1.73, 1.77 and 1.87, respectively]. Conversely, having the -116AA or +405GG genotype did not significantly increase the risk of disease expression compared with other genotypes of the same loci. Interestingly, we found that -1540AA, -1512InsIns, -1451TT, -460CC and -152AA homozygous genotypes have a significant two-fold increased risk in developing psoriasis after the age of 40 years (late-onset psoriasis) (ORs = 2.19, 2.19, 2.19, 2.05 and 2.26; P = 0.02, 0.02, 0.02, 0.04 and 0.02, respectively) as compared with controls. On the contrary, we found no phenotype-genotype association of the same magnitude among the patients in whom psoriasis developed at or before the age of 40 years (early-onset psoriasis) compared with controls. Genotype distributions were not significantly different when cases and controls were stratified either by gender or family history of psoriasis. Finally, VEGF plasma concentration was not significantly different between patients and controls and was not correlated with the severity of the disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16630077     DOI: 10.1111/j.0906-6705.2006.00416.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  11 in total

1.  Serum vascular endothelial growth factor, transforming growth factor β1, and nitric oxide levels in patients with psoriasis vulgaris: their correlation to disease severity.

Authors:  Abdel-Raheim M A Meki; Hani Al-Shobaili
Journal:  J Clin Lab Anal       Date:  2014-03-22       Impact factor: 2.352

2.  Polymorphism of VEGF gene in susceptibility to chronic immune-mediated inflammatory diseases: a meta-analysis.

Authors:  Ni Wei; Zijia Chen; Zhifeng Xue; Yuelan Zhu
Journal:  Rheumatol Int       Date:  2015-05-26       Impact factor: 2.631

3.  Four polymorphisms of VEGF (+405C>G, -460T>C, -2578C>A, and -1154G>A) in susceptibility to psoriasis: a meta-analysis.

Authors:  Min Qi; Xiaoyuan Huang; Lei Zhou; Jianglin Zhang
Journal:  DNA Cell Biol       Date:  2014-04       Impact factor: 3.311

4.  Plasma levels of vascular endothelial growth factor and fibroblast growth factor 2 in patients with major depressive disorders.

Authors:  M Takebayashi; R Hashimoto; K Hisaoka; M Tsuchioka; H Kunugi
Journal:  J Neural Transm (Vienna)       Date:  2010-08-06       Impact factor: 3.575

5.  IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin.

Authors:  Theoharis C Theoharides; Bodi Zhang; Duraisamy Kempuraj; Michael Tagen; Magdalini Vasiadi; Asimenia Angelidou; Konstantinos-Dionysios Alysandratos; Dimitris Kalogeromitros; Shahrzad Asadi; Nikolaos Stavrianeas; Erika Peterson; Susan Leeman; Pio Conti
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

6.  Substance P (SP) induces expression of functional corticotropin-releasing hormone receptor-1 (CRHR-1) in human mast cells.

Authors:  Shahrzad Asadi; Konstantinos-Dionysios Alysandratos; Asimenia Angelidou; Alexandra Miniati; Nikolaos Sismanopoulos; Magdalini Vasiadi; Bodi Zhang; Dimitrios Kalogeromitros; Theoharis C Theoharides
Journal:  J Invest Dermatol       Date:  2011-11-17       Impact factor: 8.551

7.  VEGF, FGF1, FGF2 and EGF gene polymorphisms and psoriatic arthritis.

Authors:  Christopher Butt; Sooyeol Lim; Celia Greenwood; Proton Rahman
Journal:  BMC Musculoskelet Disord       Date:  2007-01-04       Impact factor: 2.362

8.  Polymorphisms Associated with Age at Onset in Patients with Moderate-to-Severe Plaque Psoriasis.

Authors:  Rocío Prieto-Pérez; Guillermo Solano-López; Teresa Cabaleiro; Manuel Román; Dolores Ochoa; María Talegón; Ofelia Baniandrés; José Luis López-Estebaranz; Pablo de la Cueva; Esteban Daudén; Francisco Abad-Santos
Journal:  J Immunol Res       Date:  2015-11-03       Impact factor: 4.818

9.  Vascular endothelial growth factor and hypoxia-inducible factor-1α gene polymorphisms and coronary collateral formation in patients with coronary chronic total occlusions.

Authors:  Vincent Amoah; Benjamin Wrigley; Eric Holroyd; Andrew Smallwood; Angel L Armesilla; Alan Nevill; James Cotton
Journal:  SAGE Open Med       Date:  2016-06-24

10.  Genetic Risk Factors for Psoriasis in Turkish Population: -1540 C/A, -1512 Ins18, and +405 C/G Polymorphisms within the Vascular Endothelial Growth Factor Gene.

Authors:  Tuba Bozduman; Sibel Ersoy Evans; Sevilay Karahan; Yildiz Hayran; Filiz Akbiyik; Incilay Lay
Journal:  Ann Dermatol       Date:  2016-01-28       Impact factor: 1.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.